Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity

Click to increase image sizeClick to decrease image size

Acknowledgments

The author would like to thank Dr. Kathy Manger for her editorial assistance.

Declaration of interest

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

A reviewer on this manuscript has disclosed that they are a speaker for Novo Nordisk and Jansen Pharmaceuticals and are a shareholder in Zafgen and Vivus. All other peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was not funded.